Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Tensor GSVD of Patient- and Platform-Matched Tumor and Normal DNA Copy-Number Profiles Uncovers Chromosome Arm-Wide Patterns of Tumor-Exclusive Platform-Consistent Alterations Encoding for Cell Transformation and Predicting Ovarian Cancer Survival

Fig 4

Survival analyses of the discovery and validation sets of patients, as well as only the platinum-based chemotherapy patients in the discovery and validation sets, classified by the 6p+12p, 7p, and Xq tensor GSVD combined.

(a) KM curves of the discovery set of 249 patients classified by combination of the 6p+12p, 7p, and Xq x-probelet coefficients, show median survival times of 86, 52, and 36 months for the groups A, B, and C, respectively, with the corresponding log-rank test P-value < 10−3. (b) KM survival analysis of only the 218, i.e., ∼ 88% platinum-based chemotherapy patients in the discovery set, classified by combination of the three tensor GSVDs, gives qualitatively the same and quantitatively similar results to those of the analyses of 100% of the patients. This means that the combination of the three tensor GSVDs predicts survival in the platinum-based chemotherapy patient population. (c) KM curves of the validation set of 148 stage III-IV patients classified by combination of the 6p+12p, 7p, and Xq arraylet correlation coefficients, show median survival times of 72, 57, and 33 months for the groups A, B, and C, respectively, with the corresponding log-rank test P-value < 10−3. This validates the survival analyses of the discovery set of 249 patients. (d) KM survival analysis of only the 140, i.e., ∼ 95% platinum-based chemotherapy patients in the validation set, classified by combination of the three tensor GSVDs.

Fig 4

doi: https://doi.org/10.1371/journal.pone.0121396.g004